Liquidia (LQDA) Could Be 4% Undervalued Following New Pulmonary Hypertension Data
Liquidia (LQDA) stock is in focus after the company announced new data presentations on its inhaled treprostinil programs at the European Respiratory Society 2026 Congress, drawing attention to its pulmonary hypertension pipeline.
The latest data update comes after a period of sharp share price swings for Liquidia, with the stock at US$69.68 and the recent 30-day share price return down 16.9%, while the year-to-date share price return is 121.91%. The five-year total shareholder return is extremely high, which may indicate that investors are weighing long-term pipeline potential against shorter-term event risk.
Scan beyond Liquidia and compare this pulmonary hypertension story with other rare disease opportunities using our hand picked screener of 20 high quality undiscovered gems.
Liquidia now combines a focused rare disease business with a share price that has climbed sharply this year and then cooled in the past month. The next step is to ask whether that mix still adds up to a reasonable valuation.
Most Popular Narrative: 3.7% Undervalued
Based on the most followed narrative, Liquidia’s fair value of $72.38 sits modestly above the last close at $69.68, which keeps attention on the company’s earnings power and legal outcomes.
Analysts are assuming Liquidia's revenue will grow by 68.6% annually over the next 3 years.
Analysts assume that profit margins will increase from 7.7% today to 48.2% in 3 years time.
Want to understand why this biopharma stock is priced for aggressive expansion in both sales and profitability? The narrative leans on steep margin lift and a future earnings profile that treats Liquidia more like a scaled cash generator than an early commercial story. Investors may be curious which revenue ramp assumptions and profit multiple sit behind that conclusion.
Result: Fair Value of $72.38 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Liquidia story still hinges on legal outcomes around the '327 patent and on YUTREPIA demand increasing enough to justify expanded manufacturing capacity.
Find out about the key risks to this Liquidia narrative.
Another View on Liquidia Using Market Ratios
The earlier fair value work around Liquidia points to upside potential, yet the current P/E of 45x tells a different story. It is more than double the US Pharmaceuticals industry average of 16.5x, above the peer average of 21.1x, and well ahead of a 29.6x fair ratio that the market could move toward. That gap points to meaningful valuation risk if high growth expectations slip, so the key question is whether you think the current earnings outlook really justifies such a premium.
To see how the numbers compare with peers in more detail, take a closer look at the valuation breakdown with See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
With Liquidia priced for high expectations and with legal and clinical questions still open, it can be useful to move quickly and test the assumptions yourself. To weigh both sides of the story directly, start with our breakdown of 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Liquidia?
If Liquidia has your attention, do not stop here. Broaden your watchlist now so you are not late when the next opportunity starts to move.
- Target resilient companies with steady fundamentals by scanning our 75 resilient stocks with low risk scores to help balance higher risk biopharma exposure.
- Spot potential bargains early by running through the 54 high quality undervalued stocks which focuses on quality stocks trading below their assessed value.
- Strengthen your income approach by reviewing the 11 dividend fortresses and see which high yield payers might complement a growth focused holding like Liquidia.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com